The value of ¹⁸F-FDG PET/CT in the management of malignant peripheral nerve sheath tumors
- PMID: 24699907
- DOI: 10.1007/s00259-014-2756-0
The value of ¹⁸F-FDG PET/CT in the management of malignant peripheral nerve sheath tumors
Abstract
Purpose: Our objective was to determine how positron emission tomography (PET)/CT had been used in the clinical treatment of malignant peripheral nerve sheath tumor (MPNST) patients at The University of Texas MD Anderson Cancer Center.
Methods: We reviewed a database of MPNST patients referred to MD Anderson Cancer Center during 1995-2011. We enrolled 47 patients who underwent PET/CT imaging. Disease stage was based on conventional imaging and PET/CT findings using National Comprehensive Cancer Network (NCCN) guidelines. Treatment strategies based on PET/CT and conventional imaging were determined by chart review. The maximum and mean standardized uptake values (SUVmax, SUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), change in SUVmax, change in MTV, and change in TLG were calculated from the PET/CT studies before and after treatment. Response prediction was based on imaging studies performed before and after therapy and categorized as positive or negative for residual tumor. Clinical outcome was determined from chart review.
Results: PET/CT was performed for staging in 16 patients, for restaging in 29 patients, and for surveillance in 2 patients. Of the patients, 88 % were correctly staged with PET/CT, whereas 75 % were correctly staged with conventional imaging. The sensitivity to detect local recurrence and distant metastasis at restaging was 100 and 100 % for PET/CT compared to 86 and 83 % for conventional imaging, respectively. PET/CT findings resulted in treatment changes in 31 % (5/16) and 14 % (4/29) of patients at staging and restaging, respectively. Recurrence, MTV, and TLG were prognostic factors for survival, whereas SUVmax and SUVmean were not predictive. For 21 patients who had imaging studies performed both before and after treatment, PET/CT was better at predicting outcome (overall survival, progression-free survival) than conventional imaging. A decreasing SUVmax ≥ 30 % and decrease in TLG and MTV were significant predictors for overall and progression-free survival.
Conclusion: PET/CT is valuable in MPNST management because of its high accuracy in staging and high sensitivity and accuracy in restaging as well as improvements in treatment planning. MTV from baseline staging studies is predictive of survival. Additionally, change in SUVmax, TLG, and MTV accurately predicted outcomes after treatment.
Similar articles
-
Prognostic Value of 18F-FDG PET/CT in Surgical Non-Small Cell Lung Cancer: A Meta-Analysis.PLoS One. 2016 Jan 4;11(1):e0146195. doi: 10.1371/journal.pone.0146195. eCollection 2016. PLoS One. 2016. PMID: 26727114 Free PMC article. Review.
-
Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.Eur J Nucl Med Mol Imaging. 2015 Aug;42(9):1353-61. doi: 10.1007/s00259-015-3051-4. Epub 2015 Jun 12. Eur J Nucl Med Mol Imaging. 2015. PMID: 26067088
-
Positron Emission Tomography (PET) in Oncology.Cancers (Basel). 2014 Sep 29;6(4):1821-89. doi: 10.3390/cancers6041821. Cancers (Basel). 2014. PMID: 25268160 Free PMC article. Review.
-
Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with Pancreatic Cancer.J Nucl Med. 2014 Jun;55(6):898-904. doi: 10.2967/jnumed.113.131847. Epub 2014 Apr 7. J Nucl Med. 2014. PMID: 24711649
-
Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.Acad Radiol. 2013 Jan;20(1):32-40. doi: 10.1016/j.acra.2012.07.002. Epub 2012 Sep 19. Acad Radiol. 2013. PMID: 22999369
Cited by
-
Clinical diagnostic and radiographic features of recurrent intracranial malignant triton tumor in an adult: illustrative case.J Neurosurg Case Lessons. 2023 Aug 21;6(8):CASE23338. doi: 10.3171/CASE23338. Print 2023 Aug 21. J Neurosurg Case Lessons. 2023. PMID: 37728296 Free PMC article.
-
Neoplastic nerve lesions.Neurol Sci. 2022 May;43(5):3019-3038. doi: 10.1007/s10072-022-05951-x. Epub 2022 Feb 23. Neurol Sci. 2022. PMID: 35195810 Review.
-
Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023).Sarcoma. 2020 Jan 30;2020:5784876. doi: 10.1155/2020/5784876. eCollection 2020. Sarcoma. 2020. PMID: 32089640 Free PMC article.
-
Assessment of treatment responses in children and adolescents with Ewing sarcoma with metabolic tumor parameters derived from 18F-FDG-PET/CT and circulating tumor DNA.Eur J Nucl Med Mol Imaging. 2020 Jun;47(6):1564-1575. doi: 10.1007/s00259-019-04649-1. Epub 2019 Dec 18. Eur J Nucl Med Mol Imaging. 2020. PMID: 31853559
-
Primary extra-nodal non-Hodgkin lymphoma in buttock soft tissue: A rare case report.Medicine (Baltimore). 2018 Dec;97(49):e13550. doi: 10.1097/MD.0000000000013550. Medicine (Baltimore). 2018. PMID: 30544469 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical